If hyperglycemia is exacerbated by pasireotide treatment and there is increased cardiovascular risk, GLP-1 RAs (alone or in combination with metformin) should be considered as first-line therapy (77, 79, 86). The gene discussed is GLP1R; the disease is Hyperglycemia.